Dechra Pharmaceuticals PLC (LON:DPH – Get Rating)’s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 3,066 ($37.21) and last traded at GBX 3,098 ($37.60), with a volume of 149842 shares. The stock had previously closed at GBX 3,272 ($39.71).
Separately, Liberum Capital upgraded shares of Dechra Pharmaceuticals to a “hold” rating and upped their target price for the stock from GBX 4,000 ($48.55) to GBX 4,020 ($48.79) in a research note on Wednesday, February 23rd.
The firm has a market capitalization of £3.54 billion and a PE ratio of 48.84. The company has a quick ratio of 1.73, a current ratio of 2.91 and a debt-to-equity ratio of 49.57. The stock’s fifty day simple moving average is GBX 3,557.68 and its 200 day simple moving average is GBX 4,088.15.
Dechra Pharmaceuticals Company Profile (LON:DPH)
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- The Q2 Earnings Season Could Be A Bloodbath
- The Institutions Turn The Tide For Jabil
- Commercial Metals Company Is Ready To Rebound
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.